Alle Aktivitäten

FEBS Open Bio. 2025 Jan 17. doi: 10.1002/2211-5463.13969. Online ahead of print. ABSTRACT Dimethyl fumarate (DMF) is an anti-inflammatory and immunoregulatory medication used to treat multiple sclerosis (MS) and psoriasis. Its skin sensitization property precludes its topical use, which is unfortunate for the treatment of psoriasis. Isosorbide di-(methyl fumarate) (IDMF), a novel derivative of DMF, was synthesized to circumvent this adverse reaction and unlock the potential of topical delivery, which could be useful for treating psoriasis in the subpopulation of psoriatic MS patients, as well as in the general population. Here, we compared its therapeutic potential of this non-sensitizing derivative with DMF and its therapeutic version Diroximel in three skin- and neuroinflammation models: the lck-GFP zebrafish, activated BV-2 murine microglia and human T-lymphocyte Jurkat cell line. The results provide a comparative evaluation of the bioactivity of these three related chemical entities in models relevant to skin and neuroinflammation and expose several therapeutic advantages unique to IDMF. PMID:39825608 | DOI:10.1002/2211-5463.13969 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 18;317(1):286. doi: 10.1007/s00403-025-03818-7. ABSTRACT Atherosclerosis, in which chronic inflammation is also effective in it's pathogenesis, is an important cause of morbidity and mortality in psoriasis patients. Early diagnosis and management of atherosclerosis is important. Measurement of carotid intima media thickness is a method used to determine subclinical atherosclerosis. Our aim in this study is to evaluate subclinical atherosclerosis in psoriasis patients and to examine the effects of targeted therapies on atherosclerosis. This study included 105 psoriasis patients who applied to psoriasis outpatient clinic between May 2022 and December 2022. The patients' age, gender, psoriasis area severity index (PASI) and the initiated treatment agent (topical treatment, sekukinumab, iksekizumab, guselkumab, risankizumab) were noted. Carotid intima-media thickness measurements were taken at baseline and after 6 months of treatment. In patients who were treated with secukinumab, ixekizumab, risankizumab, and guselkumab, there was a statistically significant decrease in catorid-intima media thickness at 6th month when compared with the baseline measurements (p = 0,002 p < 0,001 p < 0,001 p = 0,036 p < 0,001). On the other hand, an increase in the thickness was observed in the topical treatment group. According to our study results, targeted systemic treatments contribute to the improvement of subclinical atherosclerosis in psoriasis patients, while this effect was not seen in topical treatments. These results are consistent with literature data reporting that psoriasis is a systemic inflammatory disease. PMID:39825924 | DOI:10.1007/s00403-025-03818-7 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 18;317(1):282. doi: 10.1007/s00403-024-03676-9. ABSTRACT One of the most frequently impacted locations by psoriasis is the scalp. It is seen in about 80% of psoriasis cases worldwide, and its treatment is challenging. To compare the efficacy and safety of excimer light versus topical methotrexate (MTX) 1% hydrogel in treatment of scalp psoriasis. This randomized prospective intra-patient comparative study was carried out on 30 patients with scalp psoriasis. Lesions were divided randomly into two areas: Area A and Area B. Area A received biweekly sessions of 308-nm excimer light and Area B received topical MTX 1% hydrogel once daily for 3 consecutive months. Psoriatic Scalp Severity Index (PSSI), itching score, patient satisfaction and dermoscopic red dots and white scales were used for assessment at the baseline, at the end of treatment protocol and 1 month after the last treatment session. Both treatment modalities induced significant improvement in PSSI, itching score and dermoscopic red dots and white scales (p < 0.001 for each). The mean percentage of improvement of PSSI was 75.82 ± 33.72 in Area A and 74.19 ± 31.64 in Area B with non-significant difference between both areas (p = 0.763). Moreover, the mean percentage reduction of itching score was 77.40 ± 24.61 in Area A and 67.67 ± 34.94 in Area B with non-significant difference between both areas (p = 0.430). Additionally, a notable improvement in dermoscopic red dots and white scales was observed in 83.3% of patients in Area A and in 60% in Area B at the end of treatment protocol with non-significant difference between both areas (p = 0.518) (p = 0.436). Marked patient satisfaction was noticed in both areas with non-significant difference between both areas (p = 0.433). 308-nm excimer light and topical MTX 1% hydrogel are equally safe and effective treatment options for scalp psoriasis with minimal side effects. PMID:39825943 | DOI:10.1007/s00403-024-03676-9 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 18;317(1):291. doi: 10.1007/s00403-024-03786-4. ABSTRACT This study aims to explore the measurement agreement between direct and indirect health utility measures in four chronic dermatological conditions (atopic dermatitis, hidradenitis suppurativa, pemphigus, psoriasis). Outpatients survey data collected between 2015 and 2021 were analysed. Health-related quality of life (HRQoL) outcome measures included time trade-off (TTO), EQ-5D-5L and Dermatology Life Quality Index (DLQI). Descriptive statistics were computed for the pooled sample and four diseases. Mean, standard deviation (SD), median, interquartile range (IQR), ceiling and floor effects were calculated for TTO, EQ-5D-5L and DLQI utilities. Bland‒Altman plots and intraclass correlation coefficients (ICC) were applied to investigate the agreement between health utility measures. Sociodemographic characteristics (age, sex, educational level, employment status) and health-related information (disease duration, outpatient care visits in the past 3 months and disease severity) impact on utilities was investigated by Tobit regressions. The sample includes N = 765 patient responses with a mean age of 41.5 (SD = 16.2), majority being males (52.7%). Total sample mean utilities were the highest according to TTO (0.83), followed by EQ-5D-5L and vDLQI (0.81 and 0.81) and lowest in mDLQI (0.77). Measurement agreement was found only between TTO and EQ-5D-5L. Skin-disease severity impacted all health state utilities, though only TTO differentiated utility values according to disease type. The discrepancies between the TTO and DLQI warn to compare DLQI-based utilities in different dermatological conditions with extreme caution. PMID:39825944 | DOI:10.1007/s00403-024-03786-4 Den ganzen Artikel lesen

Sci Rep. 2025 Jan 17;15(1):2346. doi: 10.1038/s41598-025-86976-y. ABSTRACT Brodalumab, a humanized monoclonal antibody that targets the interleukin-17 receptor A, is primarily used to manage moderate-to-severe plaque psoriasis. Although it has demonstrated favorable efficacy and safety in clinical trials, the strict inclusion and exclusion criteria may not fully reflect its safety profile in real-world settings. As its use becomes more widespread in clinical practice, understanding its safety in real-world applications is crucial.This study employed disproportionality analysis to assess the safety of brodalumab by examining all adverse event reports that identified brodalumab as the primary suspected drug in the FDA Adverse Event Reporting System database since 2017. Techniques such as the Reporting Odds Ratio, Proportional Reporting Ratio, Multi-item Gamma Poisson Shrinker, and Bayesian Confidence Propagation Neural Network were utilized to analyze the adverse events associated with brodalumab. Additionally, the Weibull distribution was used to model the temporal risk of adverse events.The study identified several adverse reactions already listed on the drug's label that showed positive signals, including arthralgia, headache, myalgia, suicidal ideation, oropharyngeal pain, injection site mass, and infections. Additionally, we found potential adverse reactions not noted on the drug's label that exhibited positive signals, including depression, increased blood pressure, peripheral swelling, gait disturbance, inability to walk, stress, myocardial infarction, sepsis, uveitis, nephrolithiasis, and interstitial lung disease. Moreover, this analysis highlighted the critical need for vigilant monitoring of adverse events, especially during the first month following the initiation of treatment.This study provides initial insights into the real-world safety of brodalumab, confirming known adverse reactions and uncovering additional potential risks. The results deliver vital information that can assist clinicians in making informed decisions when prescribing brodalumab for psoriasis treatment. PMID:39824966 | DOI:10.1038/s41598-025-86976-y Den ganzen Artikel lesen

Cell Mol Biol Lett. 2025 Jan 17;30(1):7. doi: 10.1186/s11658-025-00685-y. ABSTRACT The skin is a barrier that protects the human body against environmental factors (physical, including solar radiation, chemicals, and pathogens). The integrity and, consequently, the effective metabolic activity of skin cells is ensured by the cell membrane, the important structural and metabolic elements of which are phospholipids. Phospholipids are subject to continuous transformation, including enzymatic hydrolysis (with the participation of phospholipases A, C, and D) to free polyunsaturated fatty acids (PUFAs), which under the influence of cyclooxygenases (COX1/2), lipoxygenases (LOXs), and cytochrome P450 (CYPs P450) are metabolized to various classes of oxylipins, depending on the type of PUFA being metabolized and the enzyme acting. The most frequently analyzed oxylipins, especially in skin cells, are eicosanoids, which are derivatives of arachidonic acid (AA). Their level depends on both environmental factors and endogenous metabolic disorders. However, they play an important role in homeostasis mechanisms related to the structural and functional integrity of the skin, including maintaining redox balance, as well as regulating inflammatory processes arising in response to endogenous and exogenous factors reaching skin cells. Therefore, it is believed that dysregulation of eicosanoid levels may contribute to the development of skin diseases, such as psoriasis or atopic dermatitis, which in turn suggests that targeted control of the generation of specific eicosanoids may have diagnostic significance and beneficial therapeutic effects. This review is the first systemic and very detailed approach presenting both the causes and consequences of changes in phospholipid metabolism leading to the generation of eicosanoids, changes in the level of which result in specific metabolic disorders in skin cells leading to the development of various diseases. At the same time, existing literature data indicate that further detailed research is necessary to understand a clear relationship between changes in the level of specific eicosanoids and the pathomechanisms of specific skin diseases, as well as to develop an effective diagnostic and therapeutic approach. PMID:39825220 | DOI:10.1186/s11658-025-00685-y Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 16;317(1):256. doi: 10.1007/s00403-025-03810-1. NO ABSTRACT PMID:39820719 | DOI:10.1007/s00403-025-03810-1 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 17;317(1):269. doi: 10.1007/s00403-025-03808-9. ABSTRACT Psoriasis is associated with psychological distress among the affected due to unsightly skin lesions, chronicity and the cultural and social stigma linked with the disease. The pathophysiological link between psoriasis and depression creates a vicious cycle in the skin and brain axis. This study evaluates the psychological comorbidity of patients with chronic plaque psoriasis (CPP). A cross-sectional study was conducted among 297 patients aged 18 years or more attending dermatology clinics at National Hospital, Galle and General Hospitals at Matara and Hambantota. The Sinhala validated Kessler Psychological Distress Scale (K10), and patient health questionnaire (PHQ-9) were used to assess psychological status and depression, respectively. The quality of life (QoL) was assessed using the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI). Mean (SD) age of patients was 52(12) years and 57.6% were males. According to the K10 score, 73% (n = 218) were likely to be mentally robust while 15% (n = 45) had mild mental disorder and 11% (n = 34) had moderate to severe mental disorder. Screening using PHQ-9 showed 17%(n = 51) prevalence of depression and 14% (n = 42) reported to have had suicidal ideation at some stage of the illness. Psychological distress showed weak correlations with age (ρ= -0.19, p < 0.01), degree of itch (ρ = 0.16, p < 0.01), disease severity (body surface area ρ = 0.16, p < 0.01 and psoriasis area severity index ρ=+0.15, p < 0.05). Both K10 and PHQ-9 showed significant correlations with PDI (ρ = 0.51 and ρ = 0.48, p < 0.01) and DLQI (ρ = 0.34 and ρ = 0.39, p = < 0.001). The presence of arthralgia was associated with psychological distress and depression (OR 1.8, 95% CI: 1.09, 3.05: p = 0.019, and OR 2.48, 95% CI: 1.32, 4.65: p = 0.004, respectively). There was no association between the psychological distress with gender, duration of the disease, or smoking status. Psychological distress is common in patients with CPP and it is associated with reduced QoL. Depression and suicidal ideation were notable concerns, and arthralgia was linked to higher levels of distress. These findings highlight the importance of addressing both physical and mental health in managing psoriasis. PMID:39820787 | DOI:10.1007/s00403-025-03808-9 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 16;317(1):254. doi: 10.1007/s00403-025-03809-8. NO ABSTRACT PMID:39821329 | DOI:10.1007/s00403-025-03809-8 Den ganzen Artikel lesen

Arch Dermatol Res. 2025 Jan 16;317(1):268. doi: 10.1007/s00403-025-03805-y. ABSTRACT The relationship between psoriasis and osteopenia remains undetermined. Patients with psoriasis tend to have a higher Body Mass Index (BMI) compared to those without the condition. While it appears plausible that BMI could mediate this association, further study is required to confirm this hypothesis. The objective of this study is to ascertain whether BMI plays a role in influencing the impact of psoriasis on osteopenia. This study encompassed 2,624 participants from the National Health and Nutrition Examination Survey (NHANES) conducted between 2003 and 2006. The condition of psoriasis was self-reported, while osteopenia was assessed based on bone mineral density (BMD) range and self-reported osteoporosis. BMI was derived from NHANES body measurement data. Weighted logistic regression analyses and mediation analysis were utilized to elucidate the relationship. Subgroup differences were further explored in the absence of a clear relationship. A positive correlation was observed between psoriasis and osteopenia. Furthermore, BMI was positively related to psoriasis and negatively related to osteopenia. Additionally, BMI served as a mediator in the relationship between psoriasis and osteopenia, accounting for 20.8% of the variance. Specifically, the mediating influence of BMI exhibited variations based on diabetes status and gender. In conclusion, Controlling BMI could potentially mitigate the impact of psoriasis on osteopenia. Therefore, we advocate for a rigorous focus on bone health in individuals with psoriasis, particularly among males and non-diabetic populations. PMID:39821427 | DOI:10.1007/s00403-025-03805-y Den ganzen Artikel lesen

Int J Dermatol. 2025 Jan 16. doi: 10.1111/ijd.17658. Online ahead of print. NO ABSTRACT PMID:39821776 | DOI:10.1111/ijd.17658 Den ganzen Artikel lesen

Dermatol Ther (Heidelb). 2025 Jan 17. doi: 10.1007/s13555-024-01328-4. Online ahead of print. NO ABSTRACT PMID:39821856 | DOI:10.1007/s13555-024-01328-4 Den ganzen Artikel lesen

Cureus. 2024 Dec 16;16(12):e75810. doi: 10.7759/cureus.75810. eCollection 2024 Dec. ABSTRACT Introduction The COVID-19 pandemic sparked an interest in skincare with the closure of spas and salons. Skincare, one of TikTok's most popular dermatology-related hashtags, received hundreds of millions of views. The American Academy of Dermatology (AAD) shared facial cleansing recommendations; however, how many people follow them is unclear. Studies have shown a good daily facial cleansing and moisturizing routine can increase microbiome diversity and skin hydration. This can be beneficial in conditions like psoriasis, eczema, and acne. Purpose The aim of the study is to assess how well people follow the AAD recommendations and evaluate any differences in this behavior by gender. Methods A 19-question survey was designed and administered utilizing Qualtrics. The questions included demographic information, facial cleansing practices, and motivation for skincare routine. The survey was distributed via Rowan Email and on various social media platforms (GroupMe, Instagram, etc.) to target the general population. The data was analyzed using SPSS. Results One hundred twenty-four responses were collected from 91 female-identifying and 33 male-identifying participants. There were statistically significant differences between genders for the use of non-alcoholic gentle cleanser (p<0.001), use of moisturizer after washing the face (p<0.001), washing the face after sweating (p<0.001), and using warm water (p=0.026). No statistically significant difference was seen for face washing occurrence between genders (p=0.098). Statistically significant differences were seen between genders for motivation: hygiene (p<0.001), beauty/anti-aging (p<0.001), and health (p=0.004). Conclusion Individuals who identify as female may be more likely to adhere to AAD facial skincare recommendations. This could be a result of self-reported motivations such as hygiene, beauty, and health. PMID:39822430 | PMC:PMC11735236 | DOI:10.7759/cureus.75810 Den ganzen Artikel lesen

JAAD Case Rep. 2024 Sep 12;53:90-92. doi: 10.1016/j.jdcr.2024.08.027. eCollection 2024 Nov. NO ABSTRACT PMID:39823051 | PMC:PMC11736156 | DOI:10.1016/j.jdcr.2024.08.027 Den ganzen Artikel lesen

JAAD Case Rep. 2024 Sep 12;53:93-96. doi: 10.1016/j.jdcr.2024.08.030. eCollection 2024 Nov. NO ABSTRACT PMID:39823053 | PMC:PMC11736064 | DOI:10.1016/j.jdcr.2024.08.030 Den ganzen Artikel lesen

Prim Care Companion CNS Disord. 2025 Jan 9;27(1):24cr03803. doi: 10.4088/PCC.24cr03803. NO ABSTRACT PMID:39823455 | DOI:10.4088/PCC.24cr03803 Den ganzen Artikel lesen

SummaryBackground and ObjectivesIntegration of artificial intelligence in healthcare, particularly ChatGPT, is transforming medical diagnostics and …Den ganzen Artikel lesen

Mease PJ, Ferrante SA, Shiff NJ, Fitzgerald TP, Chakravarty SD, Walsh JA. Mease PJ, et al. Adv Ther. 2024 Dec 2. doi: 10.1007/s12325-024-03042-1. …Den ganzen Artikel lesen

Display options Display options Purpose: Patients' treatment expectations significantly influence the effectiveness of medical and pharmacological …Den ganzen Artikel lesen

Tunis Med. 2025 Jan 5;103(1):32-43. doi: 10.62438/tunismed.v103i1.5565. ABSTRACT AIM: To develop good practice recommendations (GPR) for the therapeutic management of patients with spondyloarthritis (SpA), including psoriatic arthritis. METHODS: Following standardised procedures, a systematic review of the literature was carried out on non-pharmacological and non-biological pharmacological treatments for SpA. The review was based on questions defined by a working group of 15 rheumatologists. The data was evaluated at group meetings, which led to the drafting of recommendations, the assignment of a grade to each recommendation and the determination of the level of agreement between the experts. RESULTS: A general principle and 11 recommendations were developed. The recommendations focus on treatment modalities, taking into account the dominant phenotype (axial, articular peripheral, enthesitic peripheral) and extra-articular manifestations (psoriasis, chronic inflammatory bowel disease (IBD)). The first recommendation concerns therapeutic patient education. Recommendations 2 to 4 focus on NSAIDs as the first-line pharmacological treatment for the various presentations of the disease, with the exception of those associated with IBD, as well as their prescribing modalities. Recommendation 5 deals with analgesics. Recommendation 6 limits the use of glucocorticoids to symptomatic peripheral arthritis and advises against their long-term use. Recommendation 7 deals with radioisotope synoviorthesis for refractory arthritis of the hips and knees. Conventional Synthetic Disease-Modifying AntiRheumatic Drugs (csDMARDs) are not recommended for SpA which is axial, enthesitic or involves dactylitis (recommendation 8). JAK inhibitors are recommended for axial SpA and for joint and skin involvement of psoriatic arthritis in failure of symptomatic treatment, csDMARDs and/or bDMARDs (recommendation 9). The latest recommendations (10-11) concern physical and surgical treatment respectively. CONCLUSION: These GPR provide a summary of the current state of the literature, with the aim of optimising the management of patients with SpA, thereby improving the quality and safety of care with a better medico-economic approach. Efforts must be made to apply, implement and communicate these recommendations. PMID:39812192 | DOI:10.62438/tunismed.v103i1.5565 Den ganzen Artikel lesen

J Dermatol. 2025 Jan 15. doi: 10.1111/1346-8138.17622. Online ahead of print. ABSTRACT Itch is a prominent symptom in many cutaneous disorders, including atopic dermatitis (AD), prurigo nodularis, and psoriasis. Itch is also a common but overlooked concern in patients with hidradenitis suppurativa (HS). Currently, the mechanisms underlying itch in HS remain unclear. To gain a better understanding, we reviewed the literature on pruritus in HS and other itch-predominant disorders, AD, and psoriasis. In HS, psoriasis, and AD, we found that itch often co-localized with pain and occurred more frequently at night. Furthermore, itch was found to negatively affect sleep and increase the risk for comorbid psychiatric disorders in HS, psoriasis, and AD. However, HS-, psoriasis-, and AD-related itch differ in temporality. Itch in AD is often described as chronic, while itch in HS and psoriasis is often described as episodic. HS-associated itch is likely multifactorial, and several mechanisms have been proposed including peripheral sensitization, central sensitization, and neuroinflammation. Prior studies in HS highlight enhanced IgE production and a dense infiltration of mast cells, along with a variety of cytokines and chemokines. Furthermore, alterations in the skin microbiome may contribute to itch in HS. To date, few therapies have been studied to treat itch in HS. Given the efficacy of several biologics and small molecules in treating itch in AD and psoriasis, similar agents may be explored in future HS studies. Alternative therapies to target neurological and psychiatric contributions to itch may include anticonvulsants, cannabinoids, and nonpharmacological treatments. In conclusion, pathomechanisms of itch in HS remain to be fully elucidated. However, we can draw on lessons from other pruritic disorders to begin addressing the symptom of it and identify important questions for future study. PMID:39812242 | DOI:10.1111/1346-8138.17622 Den ganzen Artikel lesen

Med J Malaysia. 2025 Jan;80(1):25-30. ABSTRACT INTRODUCTION: Psoriasis is a chronic inflammatory skin condition often associated with comorbidities that may impact cognitive function. This study aims to determine if psoriasis is associated with the risk of cognitive impairment and to assess the relationship between cognitive impairment and various disease-related factors, including psoriasis severity, disease duration, and the presence of psoriatic arthropathy, using the Virtual Cognitive Assessment Tool (VCAT). MATERIALS AND METHODS: A total of 160 individuals were selected, comprising 80 psoriasis patients and 80 controls, matched for age, gender, ethnicity, marital status, education levels, and prevalence of comorbidities. Cognitive function was assessed using the VCAT. The relationship between cognitive impairment and various disease-related factors, including psoriasis severity measured using Psoriasis Area Severity Index (PASI scores), disease duration, and the presence of psoriatic arthropathy, was examined. RESULTS: The mean VCAT scores for the psoriasis and control groups were 25.38 (SD = 3.18) and 25.94 (SD = 2.67), respectively, with no significant difference between the two groups (p = 0.227). While most cognitive domains showed no significant differences, the VCAT attention sub-score was significantly lower in psoriasis patients (p < 0.05). There was no significant association between psoriasis and cognitive impairment. No significant association was found between cognitive function and PASI scores nor psoriatic arthropathy. A negative association was found between disease duration and VCAT scores, suggesting longer disease duration correlates with lower cognitive function (p = 0.05). CONCLUSIONS: This study did not find broad cognitive impairment in psoriasis patients compared to controls, the specific deficit in attention and its association with the duration of psoriasis warrants further investigation. Understanding and addressing the cognitive aspects of psoriasis could significantly improve the overall quality of life for these patients. PMID:39812425 Den ganzen Artikel lesen

F1000Res. 2024 Dec 6;13:1494. doi: 10.12688/f1000research.159565.1. eCollection 2024. ABSTRACT This correspondence discusses the recent findings by Straalen et al., highlighting molecular similarities and distinctions between palmoplantar pustulosis (PPP) and dyshidrotic palmoplantar eczema (DPE). The study emphasizes shared proinflammatory pathways and T-cell-related gene upregulation while detailing unique features such as neutrophil involvement in PPP and lipid antigen processing in DPE. We elaborate on histopathological differences, especially intraepidermal vesicle formation in PPP linked to IL-1-mediated pathways and the absence of hyaluronan expression, contrasting with Th2 cytokines-driven spongiosis in DPE. By addressing IL-4, hyaluronan synthases, and keratinocyte adhesion molecules, this correspondence aims to deepen understanding of PPP and DPE pathophysiology. PMID:39810849 | PMC:PMC11729159 | DOI:10.12688/f1000research.159565.1 Den ganzen Artikel lesen

Psoriasis (Auckl). 2025 Jan 10;15:9-22. doi: 10.2147/PTT.S486338. eCollection 2025. ABSTRACT PURPOSE: Patients' treatment expectations significantly influence the effectiveness of medical and pharmacological treatments. This clinical proof-of-concept study aimed to enhance treatment outcomes by targeting positive treatment expectations of psoriasis patients beginning systemic anti-psoriatic therapy with secukinumab, an interleukin (IL)-17A antagonist. PATIENTS AND METHODS: We randomly assigned patients to three groups: a treatment as usual (TAU) group receiving the standard 300mg dose of secukinumab, a dose-control (DC) group with 75% dose reduction and an experimental (EXP) group receiving the same reduced dose along with a "cover story" designed to positively influence treatment expectations. We evaluated skin symptoms using the Psoriasis Area and Severity Index (PASI), the Dermatology Life Quality Index (DLQI), perceived itch, mood and plasma IL-17A levels at baseline and at 1, 2, 3, 4, 8, 12, and 16 weeks post intervention. RESULTS: The study included N = 120 patients (average age = 45.78 years, 34% female). A high baseline expectation level (8.1 of 10 points) was observed across all groups which could not be further increased by the EXP-group's "cover story". The EXP and DC groups did not differ with regard to reaching 75% improvement in PASI scores (PASI75), a DLQI score of 0 or 1 or at least 4 points improvement in itch. Over time, the EXP-group showed a faster decline in PASI scores and anxiety symptoms compared to the DC-group, but less improvement in quality of life. IL-17A levels significantly increased throughout the treatment, with no significant differences between groups despite the 75% dose reduction. CONCLUSION: This study demonstrates an attempt to modify patients' treatment expectations to enhance the effectiveness of pharmacological therapy with secukinumab in psoriasis patients. However, verbal suggestion alone did not significantly improve clinical outcomes, suggesting that future studies should explore alternative approaches to leverage placebo effects to the benefit of patients with psoriasis. PMID:39810930 | PMC:PMC11731016 | DOI:10.2147/PTT.S486338 Den ganzen Artikel lesen

J Inflamm Res. 2025 Jan 10;18:505-517. doi: 10.2147/JIR.S493338. eCollection 2025. ABSTRACT PURPOSE: Psoriasis is a complex inflammatory skin disorder that is closely associated with metabolic syndrome (MetS). Limited information is available on skin metabolic changes in psoriasis; the effect of concurrent MetS on psoriatic skin metabolite levels is unknown. We aimed to expand this information through skin metabolomic analysis. PATIENTS AND METHODS: Untargeted metabolomics was conducted using skin samples from 38 patients with psoriasis vulgaris with MetS (PVMS), 23 patients with psoriasis vulgaris without MetS (PVNMS), and 10 healthy controls (HC). Data analyses, including multivariate statistical analysis, KEGG pathway enrichment analysis, correlation analysis, and receiver operating characteristic curve analysis, were performed. RESULTS: Significant discrepancies were found between skin metabolites in the HC and PVNMS groups, particularly those involved in nucleotide and glycerophospholipid metabolism. Fifteen of these metabolites were positively correlated with psoriasis severity. Furthermore, MetS was found to affect the metabolic profiles of patients with psoriasis. There were some metabolites with consistent alterations in both the PVNMS/HC and PVMS/PVNMS comparisons. CONCLUSION: This study may provide new insights into the link between skin metabolism and psoriatic inflammation and the mechanism underlying the interaction between psoriasis and MetS. PMID:39810975 | PMC:PMC11730757 | DOI:10.2147/JIR.S493338 Den ganzen Artikel lesen